Neurobehavioral Disorders
Data for this study were sourced from 4 active treatment arms of 4 randomized, controlled trials conducted by the National Institutes of Health in the United States between 2006 and 2018.
Neurobehavioral Disorders
Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.
Neurobehavioral Disorders
The US Preventive Services Task Force (USPSTF) recommends screening for major depressive disorder (MDD) in adolescents aged 12 to 18 years, and recommends anxiety screening for children aged 8 to 18 years.
Neurobehavioral Disorders
Researchers examined the effect of neuropeptides orexin-A, ghrelin, and neuropeptide Y on hypersomnia and hyperphagia. Both symptoms are more common in people with bipolar disorder.
Neurobehavioral Disorders
The researchers of this study explored the impact of a blended approach (bCBT) that included both face-to-face CBT and iCBT on patients with major depressive disorder and insomnia.
Neurobehavioral Disorders
From 2016 to 2020, increases were seen in anxiety and depression among children, while decreases were observed in parent or caregiver mental health and coping with parenting demands.
Neurobehavioral Disorders
Whether major depressive disorder is a comorbidity of bipolar disorder isn’t really known. Researchers built a predictive model of major depressive disorder to bipolar disorder conversion and with the Observational Medical Outcomes Partnership validated the results across a multi-national network of patient databases.
Neurobehavioral Disorders
With transgender and gender non-conforming individuals in China subject to minority stress and, as a result a higher risk of adverse mental health issues, researchers aimed to review the findings of the research on transgender and gender non-conforming individuals in that country. By doing so researchers hope to give an outlook to further research that can guide clinical practice and policy.
Neurobehavioral Disorders
Investigators assessed the safety and efficacy of lumateperone for the treatment of bipolar I and II disorders in patients experiencing major depressive episodes.
Neurobehavioral Disorders
Suicide attempts among US adults increased from 2008 to 2019.
